MDCX
Price
$1.67Alerts
Change
-$0.02 (-1.18%)
Updated
Nov 17, 11:44 AM (EDT)
Capitalization
134.1M
Intraday BUY SELL Signals
NVS
Price
$159.17Alerts
Change
-$1.03 (-0.64%)
Updated
Nov 17, 11:52 AM (EDT)
Capitalization
308.96B
78 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDCX vs NVS

MDCX vs NVS Comparison Chart in %
View a ticker or compare two or three
VS
MDCX vs. NVS commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDCX is a StrongBuy and NVS is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MDCX with price predictions
Nov 16, 2026

MDCX's RSI Indicator stoops into oversold zone

The RSI Indicator for MDCX moved into overbought territory on November 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MDCX just turned positive on October 27, 2026. Looking at past instances where MDCX's MACD turned positive, the stock continued to rise in 17 of 23 cases over the following month. The odds of a continued upward trend are 74%.

Following a +18.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDCX advanced for three days, in 70 of 86 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDCX as a result. In 39 of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDCX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for MDCX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MDCX's P/B Ratio (-76.034) is very low in comparison to the industry average of (-1.421). P/E Ratio (-0.792) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. MDCX's P/S Ratio (0.000) is slightly lower than the industry average of (4.033).

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. MDCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

A.I.Advisor
a Summary for NVS with price predictions
Nov 16, 2026

NVS in upward trend: 10-day moving average crossed above 50-day moving average on October 22, 2026

The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 188 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.

The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.

Bearish Trend Analysis

The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 18 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 49%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVS as a result. In 38 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 46%.

The Moving Average Convergence Divergence Histogram (MACD) for NVS turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 21 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 46%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.

NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.421). P/E Ratio (24.370) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).

FUNDAMENTALS RATINGS
NVS: Fundamental Ratings
NVS
OUTLOOK RATING
1..100
79
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
PROFIT vs RISK RATING
1..100
4
SMR RATING
1..100
33
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MDCXNVS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
49%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
49%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
46%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
42%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
52%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 9 days ago
55%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 6 days ago
44%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
38%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
51%
COMPARISON
Comparison
Nov 17, 2026
Stock price -- (MDCX: $1.69 vs. NVS: $160.20)
Brand notoriety: MDCX and NVS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MDCX: 145% vs. NVS: 81%
Market capitalization -- MDCX: $134.1M vs. NVS: $308.96B
MDCX [@Pharmaceuticals: Major] is valued at $134.1M. NVS’s [@Pharmaceuticals: Major] market capitalization is $308.96B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.21T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $215.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDCX’s FA Score shows that 2 FA rating(s) are green while NVS’s FA Score has 3 green FA rating(s).

  • MDCX’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than MDCX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDCX’s TA Score shows that 3 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • MDCX’s TA Score: 3 bullish, 3 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NVS is a better buy in the short-term than MDCX.

Price Growth

MDCX (@Pharmaceuticals: Major) experienced а -7.65% price change this week, while NVS (@Pharmaceuticals: Major) price change was -2.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.62%. For the same industry, the average monthly price growth was -0.24%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

NVS is expected to report earnings on Feb 03, 2027.

Industries' Descriptions

@Pharmaceuticals: Major (-2.62% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
Interact to see
Advertisement

MDCX and

Correlation & Price change

A.I.dvisor tells us that MDCX and BMY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDCX and BMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDCX
1D Price
Change %
MDCX100%
-13.33%
BMY - MDCX
29%
Poorly correlated
-0.79%
SNY - MDCX
21%
Poorly correlated
+0.04%
MRK - MDCX
15%
Poorly correlated
-2.23%
NVS - MDCX
14%
Poorly correlated
-0.19%
AMGN - MDCX
13%
Poorly correlated
-0.72%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.19%
GSK - NVS
64%
Loosely correlated
-0.08%
BMY - NVS
53%
Loosely correlated
-0.79%
ABBV - NVS
52%
Loosely correlated
-0.16%
JNJ - NVS
52%
Loosely correlated
-1.12%
PFE - NVS
50%
Loosely correlated
-0.10%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TLIH5.430.13
+2.45%
Ten-League International Holdings Ltd
RJET20.210.07
+0.35%
Republic Airways Holdings Inc.
SLGL54.96-0.16
-0.29%
Sol-Gel Technologies Ltd
WING151.73-7.13
-4.49%
Wingstop
NOK7.69-0.38
-4.71%
Nokia Corp